Biostar Technologies focuses in medical design, transfer of technology, and tech support advising for anti-tumor small chemicals drugs.
Beijing Biostar Technologies, Ltd. was incorporated in Haidian Park, Zhongguancun Science and Technology Park, Beijing, in July 2002. The national high-tech led by the team of Chinese scientists in the United States led by Dr. Tang Li and Dr. Qiu Rongguo. The company, focusing on biomedical development, technology and transfer of anti-tumor small molecule chemical drugs, and technical service consulting, pioneered the creation of new anti-cancer drugs for epothilone in China, and its technology is at the international advanced level.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 26, 2020 | Series E | $890M | 2 | — | — | Detail |
Feb 19, 2019 | Series B | — | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Chengdu Biocity | — | Series E |
Tianchuang Capital | — | Series E |
Chengdu Venture Capital | — | Series B |